

Product Data Sheet

Rezvilutamide

 Cat. No.:
 HY-137448

 CAS No.:
 1572045-62-5

 Molecular Formula:
 $C_{22}H_{20}F_3N_3O_4S$

Molecular Weight: 479.47

Target: Androgen Receptor

Pathway: Others

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (208.56 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.0856 mL	10.4282 mL	20.8564 mL
	5 mM	0.4171 mL	2.0856 mL	4.1713 mL
	10 mM	0.2086 mL	1.0428 mL	2.0856 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer^{[1][2]}.

REFERENCES

[1]. SangjunYoo, et al. New drugs in prostate cancer. Prostate International Volume 4, Issue 2, June 2016, Pages 37-42.

2]. Veronica Mollica, et al. Molecu	ular Mechanisms Related to Hormo	one Inhibition Resistance in Pr	ostate Cancer. Cells. 2019 Jan 1	1;8(1):43.	
	Caution: Product has not been				
		ax: 609-228-5909 ark Dr, Suite Q, Monmouth	E-mail: tech@MedChemExp Junction, NJ 08852, USA	ress.com	

Page 2 of 2 www.MedChemExpress.com